fbpx

Textes d'opinion

Drug Price Controls and Pharmaceutical Innovation

Drug costs have undeniably risen more quickly than other health care costs. The share of drugs in overall Canadian health care spending went from 10.8% in 1988 to 15.7% in 2001. However, the higher drug expenses facing Canada’s health care systems are not due to price increases imposed by multinational pharmaceutical firms. Various factors explain the growth in drug spending.

Cet article est la reproduction de la Note économique de l’IEDM intitulée Drug Price Controls and Pharmaceutical Innovation sur sur le contrôle des prix des médicaments brevetés par le gouvernement fédéral

Back to top